These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 37545515)
1. Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of Grund M; Choi SJ; Powell L; Lukomski S Front Immunol; 2023; 14():1177650. PubMed ID: 37545515 [No Abstract] [Full Text] [Related]
2. Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T Tapia D; Sanchez-Villamil JI; Stevenson HL; Torres AG mBio; 2021 Jun; 12(3):e0122721. PubMed ID: 34182777 [TBL] [Abstract][Full Text] [Related]
13. Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application. Lankelma JM; Wagemakers A; Birnie E; Haak BW; Trentelman JJA; Weehuizen TAF; Ersöz J; Roelofs JJTH; Hovius JW; Wiersinga WJ; Bins AD Virulence; 2017 Nov; 8(8):1683-1694. PubMed ID: 28323523 [TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Ngugi SA; Ventura VV; Qazi O; Harding SV; Kitto GB; Estes DM; Dell A; Titball RW; Atkins TP; Brown KA; Hitchen PG; Prior JL Vaccine; 2010 Nov; 28(47):7551-5. PubMed ID: 20837078 [TBL] [Abstract][Full Text] [Related]
15. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Nieves W; Asakrah S; Qazi O; Brown KA; Kurtz J; Aucoin DP; McLachlan JB; Roy CJ; Morici LA Vaccine; 2011 Oct; 29(46):8381-9. PubMed ID: 21871517 [TBL] [Abstract][Full Text] [Related]
16. Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders. Moustafa DA; Scarff JM; Garcia PP; Cassidy SK; DiGiandomenico A; Waag DM; Inzana TJ; Goldberg JB PLoS One; 2015; 10(7):e0132032. PubMed ID: 26148026 [TBL] [Abstract][Full Text] [Related]
17. Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity Against Jiang W; Wang X; Su Y; Cai L; Li J; Liang J; Gu Q; Sun M; Shi L Front Immunol; 2022; 13():878832. PubMed ID: 35493458 [TBL] [Abstract][Full Text] [Related]
18. Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity. Pacini MF; Balbi CB; Dinatale B; González FB; Prochetto E; De Hernández MA; Cribb P; Farré C; Espariz M; Blancato VS; Magni C; Marcipar I; Pérez AR Acta Trop; 2023 May; 241():106889. PubMed ID: 36893830 [TBL] [Abstract][Full Text] [Related]
19. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Healey GD; Elvin SJ; Morton M; Williamson ED Infect Immun; 2005 Sep; 73(9):5945-51. PubMed ID: 16113315 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis. Schully KL; Bell MG; Prouty AM; Gallovic MD; Gautam S; Peine KJ; Sharma S; Bachelder EM; Pesce JT; Elberson MA; Ainslie KM; Keane-Myers A Int J Pharm; 2015 Nov; 495(2):849-61. PubMed ID: 26428631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]